Presentations.ai AI Slide Generator Automates Investor Pitch Decks and Sales PPTs for 12 Million Users – The AI PowerPoint Maker Scales Professional Slide Generation With Branding, Design and Data Werewolf Therapeutics Announces Upcoming Presentations at AACR 2022 Annual Meeting
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)…
Coherus BioSciences Appoints Rosh Dias, MD, MRCP, Chief Medical Officer
– Dr. Dias is a biotech and pharma industry executive with more than 20 years…
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
Ovid executing on its strategy to build a leading epilepsy pipeline OV329 expected to enter…
Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 15, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
INmune Bio, Inc. Announces Nine Data Presentations at AD/PD™ 2022 – International Conference on Alzheimer’s and Parkinson’s Diseases
Conference Provides First Exposure of EU and UK AD Experts to INmune Bio’s Approach of…
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination in Advanced HPV-Associated Cancers
NCI achieves the enrollment objective of thirty patients in the checkpoint inhibitor refractory arm of…
OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the…
Surface Oncology Appoints Theresa Boni as General Counsel
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology…
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) — Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated…
iSpecimen to Participate in Maxim’s 2022 Virtual Growth Conference on March 28-30, 2022
LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the…
Brickell Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Broadened strategic focus and expanded pipeline in immunology and inflammation following acquisition of rights to…
Acerus Reports Fourth Quarter and Full Year 2021 Financial Results
TORONTO, March 15, 2022 (GLOBE NEWSWIRE) — Acerus Pharmaceuticals Corporation (“Acerus” or the “Company”) (TSX:…
Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, at March ASCO Plenary Series
– Toripalimab plus chemotherapy met both primary endpoint of progression free survival and prespecified secondary…
Burning Rock to Release MRD Clinical Data on NSCLC and CRC at the Upcoming American Association for Cancer Research Annual Meeting
GUANGZHOU, China, March 15, 2022 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the…
Kamada Issues 2022 CEO Letter to Shareholders
REHOVOT, Israel, March 15, 2022 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a…
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2021 Financial Results
Revenues Grew 40% for the Fourth Quarter and 42% for Full Year 20212022 Guidance Reaffirmed…
Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Data readouts from multiple clinical trials expected during the next 6 to 12 months Strong…
Nabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc…
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
On track for top-line data in April 2022 WARRINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE)…
Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
On track to submit IND application for ENTR-601-44 targeting Duchenne muscular dystrophy in 2H 2022…